Jiansong Yuan

Dr. Jiansong Yuan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
ZBZhengqing Ba
Zhengqing Ba
YXYing Xiao
Ying Xiao
MHMing He
Ming He
DLDong Liu
Dong Liu
HWHao Wang
Hao Wang
JYJiansong Yuan
Jiansong Yuan
Advances in tumor diagnosis and treatment, especially the use of targeted therapies, have remarkably improved the survival rate of patients with renal cell carcinoma (RCC), accompanied by higher hypertension (HTN) incidence among patients with RCC, reflecting the coming of a cardio-oncologic era. Therefore, for patients with RCC and HTN simultaneously, finding risk factors for the comorbidity and giving better clinical treatment have been urgent problems. In this review, we thoroughly investigated risk factors for the comorbidity of HTN and RCC based on preclinical and clinical studies. Firstly, RCC and HTN may have common risk factors, such as obesity, smoking, and other modifiable lifestyles. Secondly, RCC and HTN may lead to each other directly or indirectly by their therapies. We then discussed measures of reducing the comorbidity and treatment of HTN in patients with RCC. We also discussed the deficiency of current studies and pointed out future directions. In conclusion, this review aims to deepen the understanding of cardio-oncology and bring benefit to the population who are at high risk of getting or have already got RCC and HTN simultaneously.

Verified
Journal Article
Open access
PDF file
JZJinghan Zeng
Jinghan Zeng
YLYilu Liu
Yilu Liu
TZTianlang Zhao
Tianlang Zhao
JYJiansong Yuan
Jiansong Yuan
WYWeixian Yang
Weixian Yang
MWMan Wang
Man Wang
Objective: We aimed to conduct a meta-analysis of treatments for large vessel coronary artery disease between drug-coated balloons and drug-eluting stents. Method: We searched databases including PubMed, Web of Science, Cochrane, CNKI, and Wanfang, and selected randomized controlled trials (RCTs) or cohort studies which compared drug-coated balloons (DCBs) with drug-eluting stents (DESs). The reference vessel diameter (RVD) should be greater than 2.75 mm. The results of 12 studies with a total of 2634 patients were included in this meta-analysis. Results: The results showed that the DCB group was not inferior to the DES group in terms of the incidence of target lesion revascularization (TLR). (RR = 1.25, 95% CI: [0.84, 1.85], p = 0.27, I2 = 0%), and the incidence of bleeding events in the DCB group was lower than that in the DES group (RR = 0.30, 95% CI: [0.15, 0.59], p = 0.0004). The results also showed that the post-intervention minimal lumen diameter (MLD) in the DCB group was smaller than that in the DES group. (RR = −0.37, 95% CI: [−0.59, −0.16], p = 0.0007), but the follow-up MLD in the DCB group was not less than that in the DES group (RR = −0.03, 95% CI: [−0.14,−0.08], p = 0.61). Additionally the DCB group had less late lumen loss (LLL) compared with the DES group. (RR = −0.31, 95% CI: [−0.60, −0.02], p < 0.0001). Conclusion: This meta-analysis confirms that in the early and late stages after percutaneous coronary intervention (PCI), DCB is not inferior in efficacy and safety to DES for de novo large coronary lesions with RVD > 2.75 mm.

9 November 2022 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
YXYing Xiao
Ying Xiao
ZBZhengqing Ba
Zhengqing Ba
SPShurui Pang
Shurui Pang
DLDong Liu
Dong Liu
HWHao Wang
Hao Wang
JYJiansong Yuan
Jiansong Yuan
Lipid-lowering therapy is of great importance in reducing the burden of atherosclerotic cardiovascular disease. Statins act as first-line therapy in the current lipid management guidelines. However, statin use is limited in (1) statin-induced adverse events, including statin-associated muscle symptoms, new-onset diabetes mellitus, drug-induced liver injuries, acute kidney injuries, cognitive effects, hemorrhagic strokes, and cataracts; (2) special populations, including pregnant and lactating patients, patients with decompensated cirrhosis, and patients on dialysis; (3) coadministration with statin-interactive drugs, such as anti-human immunodeficiency virus drugs, anti-hepatitis C virus drugs, and immunosuppressive drugs. These considerable statin-limited groups are in urgent need of safer alternative lipid-lowering options. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are attracting widespread attention for their documented safety in general populations and superior lipid-lowering properties. Therefore, questions have been raised whether PCSK9 inhibitors could be a safe alternative in patients who are intolerant to statin therapy. In this review, we discuss the safety of PCSK9 inhibitors in statin-limited conditions. We conclude that PCSK9 inhibitors are a safe alternative lipid-lowering therapy in various statin-limited conditions. Furthermore, we identify several limitations in the current literature and suggest future directions, for the refinement of lipid management regimens.

6 February 2025 in Cancer Medicine
Verified
Journal Article
Open access
YXYing Xiao
Ying Xiao
XDXin Du
Xin Du
TWTianjie Wang
Tianjie Wang
DLDong Liu
Dong Liu
HYHongzhao You
Hongzhao You
JYJiansong Yuan
Jiansong Yuan
Background: Current evidence on relationships between serum lipid biomarkers and the risk of gastrointestinal cancers remains controversial, with no consensus reached.Methods: We conducted a prospective cohort study within the Kailuan Cohort wherein 88,225 individuals with baseline information on triglyceride (TG), total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), and high‐density lipoprotein cholesterol (HDL‐C) was followed from 2006 to 2021 for the incidence of esophageal cancer (EC), gastric cancer (GC), and colorectal cancer (CRC). Cox proportional hazards models and restricted cubic spline (RCS) analysis were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Results: Increased EC risk was associated with high HDL‐C levels (HRQ4vs.Q1 = 2.50, 95% CI: 1.57–3.98), while a U‐shaped relationship between HDL‐C and EC risk was revealed in the RCS analysis (poverall ≤ 0.0001, pnonlinear = 0.02). No robust association was identified between lipid biomarkers and GC risk. In multivariable analysis, increased CRC risk was positively associated with high TC levels (HRQ4vs.Q1 = 1.42, 95% CI: 1.11–1.83, ptrend = 0.03), dose–responsely negatively associated with LDL‐C levels over quartiles (HRQ2vs.Q1 = 0.83, 95% CI: 0.66–1.02; HRQ3vs.Q1 = 0.86, 95% CI: 0.69–1.07; HRQ4vs.Q1 = 0.68, 95% CI: 0.53–0.86, ptrend = 0.02), and showed a diminished negative association with HDL‐C levels over quartiles (HRQ2vs.Q1 = 0.75, 95% CI: 0.60–0.94; HRQ3vs.Q1 = 0.76, 95% CI: 0.61–0.95; HRQ4vs.Q1 = 0.91, 95% CI 0.74–1.13, ptrend = 0.02). The subsequent RCS analysis revealed a linear negative relationship of LDL‐C (poverall = 0.004, pnonlinear = 0.67) and a U‐shaped relationship of HDL‐C (poverall = 0.05, pnonlinear = 0.02) with CRC risk. Competitive risk analysis and sensitivity analysis confirmed the stability of our results.Conclusion: We observed a U‐shaped relationship regarding HDL‐C levels with EC and CRC risk, and a linear inverse relationship between LDL‐C levels and CRC risk. Relevant serum lipid levels should be properly managed in high‐risk individuals of certain gastrointestinal cancers.

27 May 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
HWHao Wang
Hao Wang
DLDong Liu
Dong Liu
HLHanyang Liang
Hanyang Liang
ZBZhengqing Ba
Zhengqing Ba
YMYue Ma
Yue Ma
WYWeixian Yang
Weixian Yang
Background: Cardiovascular comorbidities (CVCs) affect the overall survival (OS) of patients with colorectal cancer (CRC). However, a prognostic evaluation system for these patients is currently lacking.Objectives: This study aimed to develop and validate a nomogram, which takes CVCs into account, for predicting the survival of patients with CRC.Methods: In total, 21,432 patients with CRC were recruited from four centers in China between January 2011 and December 2017. The nomogram was constructed, based on Cox regression, using a training cohort (19,102 patients), and validated using a validation cohort (2,330 patients). The discrimination and calibration of the model were assessed by the concordance index and calibration curve. The clinical utility of the model was measured by decision curve analysis (DCA). Based on the nomogram, we divided patients into three groups: low, middle, and high risk.Results: Independent risk factors selected into our nomogram for OS included age, metastasis, malignant ascites, heart failure, and venous thromboembolism, whereas dyslipidemia was found to be a protective factor. The c-index of our nomogram was 0.714 (95% CI: 0.708–0.720) in the training cohort and 0.742 (95% CI: 0.725–0.759) in the validation cohort. The calibration curve and DCA showed the reliability of the model. The cutoff values of the three groups were 68.19 and 145.44, which were also significant in the validation cohort (p < 0.001).Conclusion: Taking CVCs into account, an easy-to-use nomogram was provided to estimate OS for patients with CRC, improving the prognostic evaluation ability.

1 October 2023 in Journal of Geriatric Cardiology
Verified
Journal Article
Open access
PDF file
HLHan-Yang Liang
Han-Yang Liang
DLDong Liu
Dong Liu
HWHao Wang
Hao Wang
ZBZheng-Qing Ba
Zheng-Qing Ba
YXYing Xiao
Ying Xiao
JYJiansong Yuan
Jiansong Yuan
BACKGROUND Both lung cancer and cardiometabolic diseases are leading causes of death in China, and they share some common risk factors. However, the prevalence and long-term effect of pre-existing cardiometabolic comorbidities (CMCs) on the survival of middle-aged and elderly lung cancer patients are still not clear. METHODS We consecutively recruited 3477 non-small cell lung cancer (NSCLC) patients between January 2011 and December 2018 from four cancer specialty hospitals in China. Univariable and multivariable adjusted Cox proportional hazard models were conducted to evaluate the risk factors associated with mortality. Hazard ratio (HR) for mortality and corresponding 95% CI were calculated. RESULTS The prevalence of CMCs was 30.0% in middle-aged NSCLC patients and 45.5% in elderly NSCLC patients. Log-rank analysis presented statistically significant differences in median survival time between patients with CMCs and without CMCs in both the middle-aged group (21.0 months vs. 32.0 months, P < 0.01) and the elderly group (13.0 months vs. 17.0 months, P = 0.01). Heart failure (HR = 1.754, 95% CI: 1.436–2.144, P < 0.001) and venous thrombus embolism (HR = 2.196, 95% CI: 1.691–2.853, P < 0.001) were independent risk factors for the survival of middle-aged NSCLC patients, while heart failure (HR = 1.709, 95% CI: 1.371–2.130, P < 0.001) continued to decrease overall survival in the elderly group. Hyperlipidemia may be a protective factor for survival in middle-aged group (HR = 0.741, 95% CI: 0.566–0.971, P = 0.030). CONCLUSIONS Our findings demonstrate for the first time the prevalence and prognostic value of pre-existing CMCs in Chinese middle-aged and elderly NSCLC patients.